Today we welcome Dr. Daniel Vitt, CEO of <a href='https://imux.com'>Immunic Therapeutics</a>. With <a href='https://worldmsday.org'>World MS Day </a>being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options.In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like.<ul><li>01:22 Meet Daniel Vitt</li><li>04:54 Understanding multiple sclerosis</li><li>07:53 Evolution of the MS treatment landscape</li><li>12:08 Immunic’s lead MS therapy explained</li><li>22:57 World MS Day and what&apos;s next for Immunic</li></ul>Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/neuroscience-biotech-companies/'>11 neuroscience biotech companies you should know about</a></li><li><a href='https://www.labiotech.eu/in-depth/btk-inhibitors-multiple-sclerosis-treatment/'>The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval</a></li><li><a href='https://www.labiotech.eu/best-biotech/multiple-sclerosis-companies/'>Six biotech companies advancing multiple sclerosis therapies</a></li></ul>

<description>&lt;p&gt;Today we welcome Dr. Daniel Vitt, CEO of &lt;a href='https://imux.com'&gt;Immunic Therapeutics&lt;/a&gt;. &lt;/p&gt;&lt;p&gt;With &lt;a href='https://worldmsday.org'&gt;World MS Day &lt;/a&gt;being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options.&lt;/p&gt;&lt;p&gt;In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;b&gt;01:22&lt;/b&gt; Meet Daniel Vitt&lt;/li&gt;&lt;li&gt;&lt;b&gt;04:54 &lt;/b&gt;Understanding multiple sclerosis&lt;/li&gt;&lt;li&gt;&lt;b&gt;07:53 &lt;/b&gt;Evolution of the MS treatment landscape&lt;/li&gt;&lt;li&gt;&lt;b&gt;12:08&lt;/b&gt; Immunic’s lead MS therapy explained&lt;/li&gt;&lt;li&gt;&lt;b&gt;22:57&lt;/b&gt; World MS Day and what&amp;apos;s next for Immunic&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/neuroscience-biotech-companies/'&gt;11 neuroscience biotech companies you should know about&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/btk-inhibitors-multiple-sclerosis-treatment/'&gt;The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/multiple-sclerosis-companies/'&gt;Six biotech companies advancing multiple sclerosis therapies&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics.  With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options. In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced progr...

World MS Day Special: Immunic reveals new hope for progressive MS

Today I am welcoming two guests: Quin Wills, CEO of <a href='https://www.ochre-bio.com'>Ochre Bio</a>, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of <a href='https://www.lexogen.com'>Lexogen</a>, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.00:55: The challenges of liver disease04:44: How Lexogen supports NGS drug discovery07:29: Major transcriptomics developments10:05: Designing high quality AI data15:47: How the Ochre-Lexogen partnership began17:17: Why a specialist partner is essential for scale18:21: Lexogen delivers on the massive sequencing project21:50: Why high quality data is crucial27:02: Lexogen&apos;s role in AI discovery34:51: Future plans and directionsThis episode was produced with the support of <a href='https://www.lexogen.com'>Lexogen</a>. Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/in-depth/precision-medicine-deep-phenotyping/'>Deep phenotyping brings accuracy to precision medicine</a></li><li><a href='https://www.labiotech.eu/in-depth/spatial-transcriptomics/'>Spatial Transcriptomics: A window into disease</a></li><li><a href='https://www.labiotech.eu/trends-news/spatial-transcriptomics-readcoor-10x/'>Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions</a></li></ul>

<description>&lt;p&gt;Today I am welcoming two guests: &lt;b&gt;Quin Wills&lt;/b&gt;, CEO of &lt;a href='https://www.ochre-bio.com'&gt;Ochre Bio&lt;/a&gt;, a biotech developing RNA therapies for chronic liver disease using AI models, and &lt;b&gt;Stéphane Barges&lt;/b&gt;, CEO of &lt;a href='https://www.lexogen.com'&gt;Lexogen&lt;/a&gt;, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.&lt;/p&gt;&lt;p&gt;&lt;b&gt;00:55&lt;/b&gt;: The challenges of liver disease&lt;/p&gt;&lt;p&gt;&lt;b&gt;04:44&lt;/b&gt;: How Lexogen supports NGS drug discovery&lt;/p&gt;&lt;p&gt;&lt;b&gt;07:29&lt;/b&gt;: Major transcriptomics developments&lt;/p&gt;&lt;p&gt;&lt;b&gt;10:05&lt;/b&gt;: Designing high quality AI data&lt;/p&gt;&lt;p&gt;&lt;b&gt;15:47&lt;/b&gt;: How the Ochre-Lexogen partnership began&lt;/p&gt;&lt;p&gt;&lt;b&gt;17:17&lt;/b&gt;: Why a specialist partner is essential for scale&lt;/p&gt;&lt;p&gt;&lt;b&gt;18:21&lt;/b&gt;: Lexogen delivers on the massive sequencing project&lt;/p&gt;&lt;p&gt;&lt;b&gt;21:50&lt;/b&gt;: Why high quality data is crucial&lt;/p&gt;&lt;p&gt;&lt;b&gt;27:02&lt;/b&gt;: Lexogen&amp;apos;s role in AI discovery&lt;/p&gt;&lt;p&gt;&lt;b&gt;34:51&lt;/b&gt;: Future plans and directions&lt;/p&gt;&lt;p&gt;This episode was produced with the support of &lt;a href='https://www.lexogen.com'&gt;Lexogen&lt;/a&gt;. Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/precision-medicine-deep-phenotyping/'&gt;Deep phenotyping brings accuracy to precision medicine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/spatial-transcriptomics/'&gt;Spatial Transcriptomics: A window into disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/trends-news/spatial-transcriptomics-readcoor-10x/'&gt;Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55: The challenges of liver disease 04:44: How Lexogen supports NGS drug discovery 07:29: Major transcriptomics developments 10:05: Designing high quality AI da...

The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

Today, we&apos;re digging into a topic that&apos;s getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we&apos;re going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at <a href='https://www.cryoport.com'>Cryoport Systems</a>. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he&apos;s seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.<ul><li>01:07    Meet Dominic Clarke and Cryoport Systems</li><li>06:24   Fresh cells versus frozen cells</li><li>08:21    Why teams switch to cryopreservation late</li><li>12:37    The challenge of variability</li><li>16:47    IntegriCell when you already have a process in place</li><li>22:17    An argument for cryopreservation based on data</li><li>25:56   The future of IntegriCell and Cryoport Systems</li></ul>This episode is brought to you with the support of <a href='https://www.cryoport.com'>Cryoport Systems</a>.Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.cryoport.com/solutions/integricell/'>IntegriCell® Cryopreservation</a></li><li><a href='https://www.buzzsprout.com/1995493/episodes/17557893'>Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience</a></li><li><a href='https://www.labiotech.eu/partner/delivering-biotherapeutics-emea-cryoport/'>Cracking the code: Delivering biotherapeutics successfully across EMEA</a></li></ul>

<description>&lt;p&gt;Today, we&amp;apos;re digging into a topic that&amp;apos;s getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is &lt;b&gt;Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start&lt;/b&gt;, and we&amp;apos;re going to challenge a few long-held beliefs about how starting material should be handled. &lt;/p&gt;&lt;p&gt;My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at &lt;a href='https://www.cryoport.com'&gt;Cryoport Systems&lt;/a&gt;. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he&amp;apos;s seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;b&gt;01:07&lt;/b&gt;    Meet Dominic Clarke and Cryoport Systems&lt;/li&gt;&lt;li&gt;&lt;b&gt;06:24 &lt;/b&gt;  Fresh cells versus frozen cells&lt;/li&gt;&lt;li&gt;&lt;b&gt;08:21&lt;/b&gt;    Why teams switch to cryopreservation late&lt;/li&gt;&lt;li&gt;&lt;b&gt;12:37&lt;/b&gt;    The challenge of variability&lt;/li&gt;&lt;li&gt;&lt;b&gt;16:47&lt;/b&gt;    IntegriCell when you already have a process in place&lt;/li&gt;&lt;li&gt;&lt;b&gt;22:17&lt;/b&gt;    An argument for cryopreservation based on data&lt;/li&gt;&lt;li&gt;&lt;b&gt;25:56&lt;/b&gt;   The future of IntegriCell and Cryoport Systems&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;This episode is brought to you with the support of &lt;a href='https://www.cryoport.com'&gt;Cryoport Systems&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.cryoport.com/solutions/integricell/'&gt;IntegriCell® Cryopreservation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.buzzsprout.com/1995493/episodes/17557893'&gt;Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/partner/delivering-biotherapeutics-emea-cryoport/'&gt;Cracking the code: Delivering biotherapeutics successfully across EMEA&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled.  My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryop...

Freeze variability, not progress: strengthen your cell therapy supply chain from the start

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of <a href='https://www.labthread.com/?utm_source=labiotech&amp;utm_medium=affiliate&amp;utm_campaign=podcast'>Lab Thread</a>. Ryan&apos;s journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021.We&apos;ll explore the frustrations of fragmented lab tools that inspired Lab Thread&apos;s integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs.I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab.01:51: Meet Ryan Cawood02:31: Frustrations with early digital tools.03:19: Daily lab organization challenges.06:50: Time lost to admin tasks.11:09: Genesis of the Lab Thread concept.13:53: Integrated workflow functionality explained.17:23: Enhancing experiment reproducibility methods.20:37: Achieving compliance standards easily.26:10: The future of digital lab management.28:33: Accelerating scientific breakthroughs.This episode is brought to you with the support of <a href='https://www.labthread.com/?utm_source=labiotech&amp;utm_medium=affiliate&amp;utm_campaign=podcast'>Lab Thread</a>.Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labthread.com/?utm_source=labiotech&amp;utm_medium=affiliate&amp;utm_campaign=podcast'>Lab Thread - Your Lab, Connected</a></li><li><a href='https://www.labiotech.eu/opinion/synthace-biosciences-software-problem/'>Hiding in plain sight: how to solve bioscience’s software problem</a></li><li><a href='https://www.labthread.com/blog/lab-chaos-and-digital-dreams-the-journey-to-lab-thread'>Lab chaos and digital dreams</a></li></ul>

<description>&lt;p&gt;Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of &lt;a href='https://www.labthread.com/?utm_source=labiotech&amp;amp;utm_medium=affiliate&amp;amp;utm_campaign=podcast'&gt;Lab Thread&lt;/a&gt;. Ryan&amp;apos;s journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021.&lt;/p&gt;&lt;p&gt;We&amp;apos;ll explore the frustrations of fragmented lab tools that inspired Lab Thread&amp;apos;s integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs.&lt;/p&gt;&lt;p&gt;I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab.&lt;/p&gt;&lt;p&gt;01:51: Meet Ryan Cawood&lt;/p&gt;&lt;p&gt;02:31: Frustrations with early digital tools.&lt;/p&gt;&lt;p&gt;03:19: Daily lab organization challenges.&lt;/p&gt;&lt;p&gt;06:50: Time lost to admin tasks.&lt;/p&gt;&lt;p&gt;11:09: Genesis of the Lab Thread concept.&lt;/p&gt;&lt;p&gt;13:53: Integrated workflow functionality explained.&lt;/p&gt;&lt;p&gt;17:23: Enhancing experiment reproducibility methods.&lt;/p&gt;&lt;p&gt;20:37: Achieving compliance standards easily.&lt;/p&gt;&lt;p&gt;26:10: The future of digital lab management.&lt;/p&gt;&lt;p&gt;28:33: Accelerating scientific breakthroughs.&lt;/p&gt;&lt;p&gt;This episode is brought to you with the support of &lt;a href='https://www.labthread.com/?utm_source=labiotech&amp;amp;utm_medium=affiliate&amp;amp;utm_campaign=podcast'&gt;Lab Thread&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labthread.com/?utm_source=labiotech&amp;amp;utm_medium=affiliate&amp;amp;utm_campaign=podcast'&gt;Lab Thread - Your Lab, Connected&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/opinion/synthace-biosciences-software-problem/'&gt;Hiding in plain sight: how to solve bioscience’s software problem&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labthread.com/blog/lab-chaos-and-digital-dreams-the-journey-to-lab-thread'&gt;Lab chaos and digital dreams&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021. We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. ...

Making labs smarter for scientific breakthroughs

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions. <ul><li>01:43 Meet Stanley Qi</li><li>03:32 Founding Epicrispr</li><li>05:53 CRISPR interference and epigenome explained</li><li>10:04 Overview of GEMS gene modulation system</li><li>11:28 Reversibility and safety of epigenetic edits</li><li>18:42 Strategy for tackling multiple disease conditions</li><li>23:27 Clinical trial plans for EPI-321 candidate</li><li>30:06 Looking forward</li></ul>This episode is brought to you with the support of <a href='ttps://www.medchemexpress.com/'>MedChemExpress</a>.Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/in-depth/crispr-technology-cure-disease/'>Could CRISPR really cure these diseases?</a></li><li><a href='https://www.labiotech.eu/best-biotech/gene-therapy-companies/'>10 gene therapy companies you should know about</a></li><li><a href='https://www.labiotech.eu/best-biotech/crispr-companies/'>CRISPR technology’s next wave: Ten companies to watch</a></li></ul>

<description>&lt;p&gt;This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.&lt;/p&gt;&lt;p&gt;Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. &lt;/p&gt;&lt;p&gt;In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions. &lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;b&gt;01:43&lt;/b&gt; Meet Stanley Qi&lt;/li&gt;&lt;li&gt;&lt;b&gt;03:32&lt;/b&gt; Founding Epicrispr&lt;/li&gt;&lt;li&gt;&lt;b&gt;05:53&lt;/b&gt; CRISPR interference and epigenome explained&lt;/li&gt;&lt;li&gt;&lt;b&gt;10:04 &lt;/b&gt;Overview of GEMS gene modulation system&lt;/li&gt;&lt;li&gt;&lt;b&gt;11:28&lt;/b&gt; Reversibility and safety of epigenetic edits&lt;/li&gt;&lt;li&gt;&lt;b&gt;18:42&lt;/b&gt; Strategy for tackling multiple disease conditions&lt;/li&gt;&lt;li&gt;&lt;b&gt;23:27&lt;/b&gt; Clinical trial plans for EPI-321 candidate&lt;/li&gt;&lt;li&gt;&lt;b&gt;30:06&lt;/b&gt; Looking forward&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;This episode is brought to you with the support of &lt;a href='ttps://www.medchemexpress.com/'&gt;MedChemExpress&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/crispr-technology-cure-disease/'&gt;Could CRISPR really cure these diseases?&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/gene-therapy-companies/'&gt;10 gene therapy companies you should know about&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/crispr-companies/'&gt;CRISPR technology’s next wave: Ten companies to watch&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr. Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.  In this episode we discuss epigenetic editing, why it’s reversible, and how it...

How Epicrispr is leveraging CRISPR without cutting DNA

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Beyond Biotech - the podcast from Labiotech

Details

Recent Episodes